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Abstract
Background: Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection
conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.
Methods/Principal Findings: We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen of a low-
cost killed whole cell OCV in residents 1 year of age and older living in 3,933 clusters in Kolkata, India. The primary endpoint
was culture-proven Vibrio cholerae O1 diarrhea episodes severe enough to require treatment in a health care facility. Of the
66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients), 38 vaccinees and 128 placebo-recipients
developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%CI lower bound=53%, p,0.001).
Vaccine protection during the third year of follow-up was 65% (one-sided 95%CI lower bound=44%, p,0.001). Significant
protection was evident in the second year of follow-up in children vaccinated at ages 1–4 years and in the third year in older
age groups.
Conclusions/Significance: The killed whole-cell OCV conferred significant protection that was evident in the second year of
follow-up in young children and was sustained for at least three years in older age groups. Continued follow-up will be
important to establish the vaccine’s duration of protection.
Trial Registration: ClinicalTrials.gov NCT00289224.
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Introduction
Cholera is a major global public health problem, causing both
epidemic and endemic disease. Although conventional, injectable
cholera vaccines have been abandoned as public health tools,
modern oral cholera vaccines (OCVs) have been found to be safe
and effective [1]. A recently revised World Health Organization
(WHO) position paper expands the potential role of vaccination as
a preventive tool against both endemic and epidemic cholera [2].
There are two licensed OCVs currently available: one
containing cholera toxin B subunit (BS) and killed cholera whole
cells (WC), which is licensed in over 50 countries, and the other
containing only killed WC, which is licensed in India and Vietnam
[1,3]. A field trial of BS-WC vaccine in Bangladesh found that a
three-dose regimen was safe and conferred high grade (85%) short-
term protection against cholera; protection was clearly evident
throughout the first two years of follow-up, but markedly declined
in the third year [4]. An advantage of the WC-only vaccine is its
low cost, now at $1.85 per dose to the public sector. We conducted
a placebo-controlled, randomized trial to assess the safety and
protection conferred by a two-dose regimen of the WC-only
vaccine against cholera severe enough to warrant solicitation of
www.plosntds.org 1 October 2011 | Volume 5 | Issue 10 | e1289medical care. An initial analysis of an ongoing field trial in Kolkata
of the WC-only vaccine found a two-dose regimen to be safe and
to confer 67% protective efficacy against cholera at two years of
follow-up [5]. Here we present results from the third year of
follow-up of the Kolkata trial.
Methods
Details on the study site, study agents, study procedures, and
assembly of subjects for this parallel, randomized trial were
previously reported [5].The study was performed in a cholera-
endemic area in the slums of Kolkata, encompassing a population
of ,109,000. Residents who were at least one year of age and
were not pregnant were eligible to participate in the study.
Interventions and Allocation
Each dose of the killed WC OCV (Shanchol
TM, Shantha
Biotechnics), contains inactivated Vibrio cholerae 01 cells represent-
ing the El Tor and classical biotypes and the Inaba and Ogawa
serotypes, as well as serogroup 0139 cells. Vials containing
identical–appearing heat-killed Escherichia coli K12 cells were used
as placebo. Single-dose vials were labeled with one of four letter
codes, two for vaccine and two for placebo. Project staff and study
subjects were unaware of the identities of the codes. Participants
were randomly assigned, by residential dwelling, to vaccine or
placebo groups. Randomization was done before enrollment by an
independent statistician (AD), using a random number table.
Dwellings were randomized in blocks of 4, corresponding to the 4
code letters used to label vaccine and placebo, within strata
defined by the ward of residence and the number of residents in
the dwelling (six strata). Each agent was given as a two-dose
regimen with an inter-dose interval of at least 14 days. Enrollment
and administration of the pre-assigned agents was performed by
dosing teams in vaccination centers serving the population. Codes
were kept secretly at Shantha Biotechnics and the International
Vaccine Institute by staff who were not involved with the trial. The
agents were administered in two rounds in 2006: from July 27 to
August 13 and from August 27 to September 10, 2006.
Study Procedures and Definitions
Surveillance was performed in nine community clinics estab-
lished for the trial and in two hospitals serving the study
population. Study physicians completed structured study forms
to obtain pertinent clinical information, and fecal specimens were
tested for V. cholerae as previously described, including identifica-
tion of 01 and 0139 serogroups with agglutination tests. Biotype
was ascertained for all 01 isolates, and the biotype of the cholera
toxin genetically encoded was identified as previously described
[5,6]. Confirmation that the subject had indeed visited the
treatment site on the date of the visit was assessed through
domiciliary visits for all patients whose samples yielded V. cholerae
O1 or O139. A diarrheal visit was defined as having, in the
24 hours before presentation: 3 or more loose or liquid stools; or,
at least 1 loose or liquid stool with blood; or, if 1–2 or
indeterminate number of loose or liquid stools were reported,
the patient must have exhibited at least some evidence of
dehydration, using WHO criteria [7]. The onset of a diarrheal
visit was the day on which the patient first reported loose or liquid
stools. Diarrheal visits for which the date of onset was less than or
equal to 7 days from the date of discharge for the previous visit
were grouped into the same diarrheal episode. The onset of a
diarrheal episode was the onset of the first diarrheal visit of the
episode. The primary endpoint, a cholera episode, was defined as
a diarrheal episode in which no component visit was described as
bloody, in which a fecal specimen yielded V. cholerae O1, and a
domiciliary check confirmed that the subject had indeed visited the
treatment center for diarrhea on the recorded date of presentation.
Demographic surveillance for migrations and deaths among the
study population was maintained during the three years of follow-
up, and verbal autopsies were done for identified deaths.
Analysis
The sample size calculation for the trial was previously reported
[5]. Prior to the analysis, data were frozen, and a detailed analytic
plan was approved by the data and safety monitoring board. The
primary analysis was a per-protocol analysis of vaccine protection
among subjects who completely ingested two doses of an agent
with the assigned treatment code, and included first cholera
episodes with onsets between 14 days and 1,095 days after receipt
of the second dose. A modified intention-to-treat analysis was done
for all individuals who received at least one dose of an agent
regardless of the amount ingested, and regardless of whether the
agent received was as assigned. First cholera episodes that began
from 1 to 1,095 days after the intake of the first dose were included
in this analysis. All analyses were conducted and interpreted prior
to unblinding of the codes.
Survival analyses were used to calculate vaccine protective
efficacy with measurements of the time to the first episode of
cholera, censoring the follow-up of individuals who died or
migrated out [8]. Kaplan-Meier curves were constructed for
descriptive analyses. We also fitted unadjusted and adjusted Cox
proportional hazards regression models, after verifying that the
proportionality assumptions were fulfilled for all independent
variables [9–11]. We estimated the hazard ratios by exponentiat-
ing the coefficient for the vaccine variable in these models and
calculated the vaccine efficacy (PE) as : (1- hazard ratio)6100%.
To estimate P values and confidence intervals (CI) for the hazard
ratio, we used the standard errors for the coefficients. Robust
sandwich variance estimates were used to account for the design
effect of cluster randomization, allowing inferences for vaccine
efficacy at the individual level [12].
Variables used for stratified randomization as well as baseline
variables that were found to be significantly associated with time to
Author Summary
New-generation vaccines against cholera are given orally,
to stimulate intestinal immunity. An internationally avail-
able oral cholera vaccine (OCV) consists of killed vibrio
whole cells together with the B subunit of cholera toxin, is
safe, and protects vaccinated individuals against cholera
for two years, but this vaccine has seen limited use due to
its high cost. We developed a simpler, inactivated whole-
cell only OCV that can be produced inexpensively and
might therefore be attractive for use in developing
countries, as well as for travelers from industrialized
countries. We tested this new OCV in a randomized,
controlled field trial that enrolled 69,328 individuals aged
one year and older living in urban slums of Kolkata, India.
At three years of follow-up after receiving at two-dose
regimen of this OCV, the vaccinated population experi-
enced 66% protection against all episodes of cholera
occurring during the three years, and 65% protection
against episodes occurring during the third year. Signifi-
cant protection was evident in the second year in children
vaccinated at ages 1–4 years and in the third year in
persons vaccinated at ages of five years and older. Follow-
up of the study population will continue for five years to
ascertain the duration of vaccine protection.
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doi:10.1371/journal.pntd.0001289.g001
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independent variables in the final models assessing vaccine
efficacy. To avoid overfitting the models, we used a backward
elimination algorithm to select independent variables in addition
to the vaccination variable. Vaccine efficacy was evaluated in
different subgroups that were defined prior to analyses. Hetero-
geneity of vaccine protection was assessed in these subgroups by
analyzing interaction terms in the models. All P values and
confidence intervals(CI’s) were calculated as one-sided except for
assessing heterogeneity of vaccine efficacy in different subgroups,
for which stochastic estimates were two-sided. An interim analysis
at 2 years of follow-up, using the Haybittle-Peto rule, set the P
value for statistical significance for the primary analysis of PE at
P,.01 [13]. Because the three-year analysis was the major
objective of the trial, all analyses reported in this paper were
evaluated at a threshold of P,.0.05, with corresponding one-sided
95% CIs. All statistical analyses were performed using SAS version
9.1. While the initial plan for surveillance was only for three years,
follow-up is ongoing to assess the duration of protection up to five
years post-vaccination.
Ethics and Monitoring
The study protocol was approved by the ethics committee of the
National Institute of Cholera and Enteric Diseases, the Health
Ministry Screening Committee of India and the International
Vaccine Institute Institutional Review Board. Written informed
consent was obtained from older residents and from the guardians
of residents aged 1 to 17 years of age. Additional written assent
was obtained from residents aged 12 to 17 years. An independent
data and safety monitoring board reviewed the study protocol,
assessed serious adverse events, and approved freezing of data and
the analytical plan prior to starting the analysis.
Results
The study was prospectively registered at ClinicalTrials.gov
(NCT00289224). In the per-protocol analysis, there were 1,721
clusters and 31,932 participants in the vaccine group and 1,757
clusters and 34,968 participants in the placebo group (Figure 1). In
the intention-to-treat analysis, there were 1,727 clusters and 33,127
participants in the vaccine group and 1,768 clusters and 36,202
participants in the placebo group. 4,252 and 4,661 participants in
the vaccine and placebo groups, respectively, died or migrated out
of the study area after the second dose. As previously reported,
individual-level and cluster-level baseline characteristics were
similar for vaccinees and placebo recipients [5]. There were no
substantive imbalances in baseline variables among participants in
each arm who were excluded or lost to follow-up.
All detected cholera episodes were due to V. cholerae 01, El Tor
biotype that genetically encoded classical biotype cholera toxin. As
shown in Table 1, 38 and 128 episodes were detected in per-
protocol analysis of the vaccine and placebo groups, respectively
(adjusted cumulative protective efficacy 66%, one-sided 95% CI-
lower bound=53%, p,0.001). In the intention-to-treat analysis,
there were 49 and 137 cholera episodes in the vaccine and placebo
groups (adjusted cumulative PE=61%, one-sided 95% CI lower
bound=47%, p,0.001). Survival curves for each analysis are
presented in Figure 2. Most of the isolates were Ogawa serotype.
In the per-protocol analysis of protective efficacy against Ogawa
cholera, there were 34 and 118 episodes, respectively, in the
vaccine and placebo groups (adjusted PE=68%, one-sided 95%
CI lower bound=54%, p=,0.001). Inaba serotype was detected
in only 4 and 10 episodes in the vaccine and placebo groups,
respectively (unadjusted PE=56%, one-sided 95% CI lower
bound=214%, p=.08). There were no deaths due to cholera
identified in the the treatment centers, or due to acute watery
diarrhea in verbal autopsies among study participants.
Table 1 presents the per protocol analysis by year of follow-up
and by age at vaccination. Cumulative three-year vaccine efficacy
was highest for children vaccinated at ages 5–14 years (adjusted
PE 88%, one-sided 95% CI lower bound=71%, P,.001),
intermediate for persons vaccinated at older ages (61%, one-sided
95% CI lower bound=37%, P,.001), and lowest for children
vaccinated at ages 1–4 years (adjusted PE 43%, one-sided 95%
lower bound=7%, P=.03), and differed significantly (P=.02,
Table 1. Per protocol analysis of the occurrence of cholera in
recipients of the killed WC OCV or K12 Escherichia coli placebo
by age and year of follow-up after the second dose in Kolkata.
Age Group WC K12
Adjusted PE; 95% LB; P
value*
(Unadjusted PE; 95% LB; P
value)
Year 1 ,5 yrs N 2,082+ 2,263 17%; 283%; 0.35
Episodes 8 (3.95){ 10 (4.55) (13%; 289%; 0.38)
5–14 yrs N 7,023 7,698 81%; 212; 0.06
Episodes 1 (0.15) 6 (0.80) (82%; 28%; 0.06)
15+ yrs N 22,827 25,007 66%; 225%; 0.09
Episodes 2 (0.09) 7 (0.29) (69%; 216%; 0.07)
Total N 31,932 34,968 45%; 25%; 0.07
Episodes 11 (0.35) 23 (0.68) (48%; 1%; 0.04)
Year 2 ,5 yrs N 1,993 2,154 81%; 33%; 0.02
Episodes 2 (1.03) 13 (6.24) (83%; 43%; 0.009)
5–14 yrs N 6,743 7,451 92%; 54%; 0.009
Episodes 1 (0.15) 13 (1.79) (92%; 53%; 0.009)
15+ yrs N 21,796 23,861 62%; 7%; 0.04
Episodes 6 (0.28) 19 (0.82) (65%; 17%; 0.02)
Total N 30,532 33,466 77%; 55%; ,.001
Episodes 9 (0.30) 45 (1.39) (78%; 57%; ,.001)
Year 3 ,5 yrs N 1,895 2,037 37%; 247%; 0.18
Episodes 6 (3.23) 9 (4.51) (28%; 270%; 0.26)
5–14 yrs N 6,458 7,098 89%; 62%; 0.002
Episodes 2 (0.32) 22 (3.16) (90%; 66%; ,.001)
15+ yrs N 20,623 22,542 64%; 32%; 0.004
Episodes 10 (0.50) 29 (1.32) (62%; 31%; 0.004)
Total N 28,976 31,677 65%; 44%; ,.001
Episodes 18 (0.64) 60 (1.94) (67%; 47%; ,.001)
Total ,5 yrs N 2,082 2,263 43%; 7%; 0.03
Episodes 16 (2.75) 32 (5.10) (46%; 12%; 0.02)
5–14 yrs N 7,023 7,698 88%; 71%; ,.001
Episodes 4 (0.20) 41 (1.89) (89%; 75%; ,.001)
15+ yrs N 22,827 25,007 61%; 37%; ,.001
Episodes 18 (0.28) 55 (0.79) (64%; 43%; ,.001)
Total N 31,932 34,968 66%; 53%; ,.001
Episodes 38 (0.43) 128 (1.31) (68%; 55%; ,.001)
*Protective efficacy (PE), one-sided lower boundary of 95% confidence interval
(CI), and one-sided P value for PE.
+Number at risk at onset of cited follow-up period.
{Number and (rate per 1,000-person years) of cholera episodes in cited group.
doi:10.1371/journal.pntd.0001289.t001
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groups was 65% during the third year of follow-up (one-sided 95%
CI lower boundary=44%, P,.001), and showed no evidence of
decline over time (P=.24, two-sided, for comparison of PE in
years 1, 2, and 3 of follow-up). Variations in vaccine protection for
each age group, by year of follow-up, did not reach statistical
Figure 2. Kaplan-Meier survival curves for the time to first episode of cholera in the per protocol (top) and intention-to-treat
(bottom) analyses of the field trial of the killed WC OCV tested in Kolkata.
doi:10.1371/journal.pntd.0001289.g002
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and 3 of follow-up in the 1–4 year, 5–14 year, and $15 year age
groups were .11, .87, and .98, respectively). Vaccine protection
was significant during the third year in the 5–14 year and $15
year age groups, but was significant only in the second year in
follow-up of younger persons.
Discussion
Our findings demonstrate that a two-dose regimen of the killed,
WC OCV conferred protection of 66% protection during the
three years following vaccination. Vaccine protection was clearly
evident in the third year of follow-up in persons vaccinated at ages
five years and older and during the second year in children
vaccinated at 1–4 years of age. Due to small numbers of outcomes
during the third year, however, further follow-up will be required
to assess the duration of protection in the youngest age group.
Protection was clearly evident against El Tor Ogawa, and
suggestive against El Tor Inaba, though the latter analysis was
limited by a small number of outcome events. Of note, all episodes
of cholera were due to V. cholerae 01 that manifested the El Tor
phenotype but genetically encoded classical biotype cholera toxin,
a hybrid strain that now accounts for nearly all cholera cases in
many parts of both Africa and Asia and that may be associated
with cholera of increased severity [6,14,15].
An apparently counterintuitive finding was that vaccine
protection was lower in the first year of follow-up than in the
subsequent two years. However, the most likely explanation for
this finding is chance variation, as there were no significant
differences in estimates of vaccine protection, either for all age
groups combined or for the ,5 year , 5–14 year, and $15 year
age groups individually, during the three years of follow-up.
Comparing the results of different vaccines tested in different
trials provides less conclusive evidence of their comparative
efficacy than head-to-head comparisons of vaccines in the same
trial. Nevertheless, it is of interest to contrast the long-term results
for the killed WC OCV studied in this trial with those for the killed
BS-WC OCV tested in three doses in Bangladesh in the 1980s, the
only evaluation of BS-WC with long-term follow-up [4]. In
contrast to the trial of killed WC OCV in Kolkata, which
demonstrated efficacy during the third year of follow-up, BS-WC
vaccine’s protection against cholera in Bangladesh was significant
only during the first two years of follow-up. Of interest, protection
by BS-WC vaccine in the Bangladesh trial was also lowest and of
shortest duration in the under-five age group, an observation that
has been attributed to the lower level of pre-existing, anti-cholera
immunity in this group, owing to less exposure to natural cholera
infections in the youngest group.
It should be emphasized, however, that long-term protection is
onlyone considerationfortheuse ofanOCV.Enhanced short-term
protection may be a distinct advantage when considering the use of
a vaccine in self-limited outbreaks of cholera. In this respect, the BS-
WC OCV has been shown to confer 85% protection lasting 4–6
months after dosing [16], Another advantage of BS-WC OCV is its
ability to confer cross-protection against LT-producing enterotoxi-
genic Escherichia coli diarrhea for several months after dosing [17].
The potential of the killed WC OCV tested in this study for use
in control of endemic and epidemic cholera is substantial.
However, much remains to be done. The study remains blinded
and surveillance will continue to assess the duration of protection
provided by the vaccine up to five years after dosing. Increasing
access to this vaccine is important, not only in India, where it is
currently licensed, but also in other cholera-endemic countries.
Access should be increased in the near future by WHO
prequalification of the vaccine so that it may be purchased by
UN agencies for use in other countries for disease control.
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